Obesity
Pila Pharma stands out in next-generation obesity pipeline
Obesity has become one of the world's biggest health challenges, and the success of long-acting GLP-1 drugs has made the area a...
Novo and Lilly in battle over blood sugar, weight and heart health
Over the past two days, Eli Lilly and...
Fierce battle for first place in the obesity race
In just a few years, obesity treatments have gone from...
Semaglutide patent expiration opens the door to Chinese generics
Semaglutide, known as Ozempic for diabetes and Wegovy...
Novo Nordisk restructures and lowers forecast
Novo Nordisk is implementing a comprehensive restructuring to...
Novo Nordisk shows its forefoot in clinical practice
The battle over the obesity market is constantly intensifying and the attacks are intensifying...
Global giants make record investments in Chinese innovations
Amidst economic challenges and looming patent expirations,...
Eli Lilly's oral GLP-1 achieves phase III success
The battle for supremacy in the obesity market continues and in...
Superluminal and Lilly in billion-dollar deal for new obesity drugs
The American drug developer Superluminal Medicines announced yesterday that...
Obesity research finds findings in “junk DNA”
Can small, hidden proteins in our cells be...
The new era of weight loss: Does GLP-1 live up to expectations?
GLP-1 drugs such as Wegovy and Mounjaro have been globally acclaimed...
In the shadow of the GLP-1 hype: new report criticizes pharmaceutical companies' patent strategies
A new report from the patent organization I-MAK sheds light...